Management of refractory autoimmune hemolytic anemia via allogeneic stem cell transplantation.
Harvard Medical School, Boston, MA, USA.
L
L
Rotenstein
Department of Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA.
A
A
Nathan
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
I
I
Ghobrial
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
J
J
Antin
Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
A
A
Parnes
D000744:Anemia, Hemolytic, Autoimmune / Q000209:etiology / Q000628:therapy*; D019468:Disease Management; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008232:Lymphoproliferative Disorders; D008875:Middle Aged; D016879:Salvage Therapy / Q000379:methods*; D020123:Sirolimus / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use; D014184:Transplantation, Homologous; D008258:Waldenstrom Macroglobulinemia / Q000150:complications / Q000473:pathology / Q000628:therapy*
D007166:Immunosuppressive Agents; D020123:Sirolimus; D016559:Tacrolimus